The road less travelled
The path less travelled can take us in interesting and unknown directions
We often talk about innovation on BSB and how hard it is to blaze a new path in oncology drug development.
Sometimes what it requires is a different way to think about a target or a new approach to modulating a pathway.
In our latest post AACR23 review, we are taking a closer look at more gems from the poster hall and how some companies and researchers are thinking differently.
Taking the road less travelled is inevitably a balance of risk and reward with plenty of challenges to overcome, which by definition is part of what makes oncology new product development such a challenging yet stimulating area…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
